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Background: Schizophrenia is linked to the7 nicotinic acetylcholine receptor and to duplicated genes encoding truncated
dup7 and dup7 subunits.
Results: Fluorescently labeled duplicated subunits display FRETwith7. Electrophysiology shows that duplicated subunits and
7 form heteropentamers with altered responses to choline and varenicline.
Conclusion: Duplicated subunits co-assemble with 7, forming functional receptors.
Significance: Such heteropentameric receptors could play a role in schizophrenia.
The 7 nicotinic acetylcholine receptor gene (CHRNA7) is
linked to schizophrenia. A partial duplication of CHRNA7
(CHRFAM7A) is found in humans on 15q13–14. Exon 6 of
CHRFAM7Aharborsa2-bpdeletionpolymorphism,CHRFAM7A-
2bp, which is also associated with schizophrenia. To under-
stand the effects of the duplicated subunits on 7 receptors, we
fused7, dup7, and dup7 subunits with various fluorescent
proteins. The duplicated subunits co-localized with full-length
7 subunits in mouse neuroblastoma cells (Neuro2a) as well as
rat hippocampal neurons. We investigated the interaction
between the duplicated subunits and full-length 7 by mea-
suring Fo¨rster resonance energy transfer using donor recovery
after photobleaching and fluorescence lifetime imagingmicros-
copy. The results revealed that the duplicated proteins co-as-
semble with 7. In electrophysiological studies, Leu at the
9-position in the M2 membrane-spanning segment was
replaced with Cys in dup7 or dup7, and constructs were
co-transfected with full-length7 inNeuro2a cells. Exposure to
ethylammonium methanethiosulfonate inhibited acetylcho-
line-induced currents, showing that the assembled functional
nicotinic acetylcholine receptors (nAChRs) included the dupli-
cated subunit. Incorporation of dup7 and dup7 subunits
modestly changes the sensitivity of receptors to choline and
varenicline. Thus, the duplicated proteins are assembled and
transported to the cell membrane together with full-length 7
subunits and alter the function of the nAChRs. The character-
ization of dup7 and dup7 as well as their influence on 7
nAChRsmay help explain the pathophysiology of schizophrenia
and may suggest therapeutic strategies.
Schizophrenia is a complex neuropsychiatric disorder. Its
heterogeneity, incomplete penetrance, and environmental fac-
tors provide challenges for identifying genetic defects. On-line
Mendelian Inheritance in Man now lists more than 200 candi-
date genes for schizophrenia susceptibility. Many genes have
been associated with schizophrenia, yet there is no definitive
genetic model. The etiology may involve a set of genes predis-
posing to the illness (1, 2).
One of the replicated candidate genes for schizophrenia is
the7 nicotinic acetylcholine receptor (nAChR)2 subunit gene,
CHRNA7. Both pharmacological and genetic studies support a
potential link between the 7 nAChR and the pathophysiology
of schizophrenia. The expression of the 7 receptor, as mea-
sured by -bungarotoxin binding, is decreased in postmortem
hippocampus, cortex, and thalamus of schizophrenic subjects
(3–6). Moreover, CHRNA7 localized at 15q14 is linked to the
P50 auditory sensory processing deficit in schizophrenia by
genetic and neurobiological studies (7, 8). Polymorphisms in
the 5 upstream regulatory region and intron 2 of CHRNA7 are
associated with both schizophrenia and the sensory processing
deficit (9, 10).
The human CHRNA7 gene is partially duplicated. Exons
5–10 of CHRNA7 and additional DNA (200 kbp) were dupli-
cated upstream, interrupting a second partial duplication of
four exons from the geneULK4 on chromosome 3 (11, 12). This
duplication appears to be a relatively recent event unique
to humans (13). The partially duplicated chimeric gene,
CHRFAM7A, is located at 15q14 1.6 Mb centromeric to the
full-length gene, and it is almost always in the opposite orien-
tation toCHRNA7. In this duplication, exons 5–10, intervening
introns, and the 3-untranslated region of CHRNA7 are con-
served. The gene product, dup7, lacks the signal peptide and
part of the binding site but contains all of the 7 membrane-
spanning regions. Mutation screening in human DNA and
mRNA identified a 2-bp deletion polymorphism in exon 6 of
CHRFAM7A (14). The partial duplication with the 2-bp dele-
tion, CHRFAM7A2bp, is almost always in the same orienta-
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tion as CHRNA7 (15). The 2-bp deletion in exon 6 causes a
frameshift in translation, resulting in a smaller gene product,
dup7, which lacks nearly the entire ligand-binding site com-
pared with dup7.CHRFAM7A2bp is significantly associated
with schizophrenia (16, 17), suggesting that the duplicated gene
might contribute to cognitive impairment.
The gene products ofCHRFAM7A, bothmRNA and protein,
are found in brain and also in the periphery (11). When
expressed alone in cell lines orXenopus oocytes heterologously,
the protein product of CHRFAM7A, dup7, is detected at low
levels, but no functional receptor is observed (18).When either
dup7 or dup7, the protein product of CHRFAM7A2bp, is
co-expressed with 7 in Xenopus oocytes, it reduces the ampli-
tude of the acetylcholine (ACh)-evoked currents, and two pre-
vious studies show that the reduction increases with the dose of
dup7 (19, 20). The pharmacology of the expressed receptors
shows differences from that of the 7 heteromer (20). Immu-
nological studies in GH4C1 cells show that dup7 reaches the
plasma membrane (20). The authors of these previous studies
suggest that CHRFAM7A acts as a dominant negative modula-
tor ofCHRNA7 function in humans and thusmay be critical for
receptor regulation (19, 20).
This study further characterizes the role of CHRFAM7A by
investigating how dup7 and dup7 exert their effects on the
full-length 7 nAChR. We have studied the interaction
between fluorescently labeled duplicated and full-length sub-
units in mouse neuroblastoma cells (Neuro2a) using imaging
techniques. We concentrated on the possible stoichiometry of
the assembled complexes. We have also performed electro-
physiology recordings to examine the receptor properties. We
confirm that the duplicated subunits are assembled and trans-
ported to the cell membrane together with full-length 7 and
thus alter the function of the nAChRs.Our results contribute to
the understanding of the pathophysiology of schizophrenia and
suggest therapeutic strategies.
EXPERIMENTAL PROCEDURES
Reagents—Unless otherwise indicated, all chemicals for cul-
ture were purchased from Invitrogen, and all chemicals for
electrophysiology were purchased from Sigma.
Plasmid Constructs—Human 7, dup7, and dup7 cDNA
clones in pcDNA 3.1 were described previously (19). The fluo-
rescent protein (FP) cassette, containing an Ala-Gly-Ala linker
flanking the FP open reading frame on both sides, was fused
into the M3-M4 loop of the subunits (21). The fusion site was
chosen as described previously (22). Mutations were intro-
duced using the QuikChange kit from Stratagene (La Jolla, CA)
according to the manufacturer’s instructions.
CellCultureandTransfections—MouseNeuro2a cells obtained
from American Type Culture Collection (ATCC) were main-
tained in 45% Dulbecco’s modified Eagle’s medium (DMEM),
45% Opti-MEM, 10% fetal bovine serum (FBS) and supple-
mented with penicillin and streptomycin. Neuro2a cells were
transfectedwith BioT (Bioland Scientific LLC, Paramount, CA)
according to the manufacturer’s instructions. Plasmid concen-
trations used for transfection were as follows: for imaging, 1 g
of each fluorescently labeled nAChR subunit; for competition
experiments, 500 ng of each fluorescently labeled subunit  1
g of untagged subunit; for recording, 1 g of each fluores-
cently labeled nAChR subunit  200 ng of RIC-3. Rat hip-
pocampal neurons were dissociated from day 18 rat embryos
and plated on 35-mm glass-bottomed imaging dishes (MatTek,
Ashland, MA) as described previously (23). Neurons were
transfected after 7 days in culture using Lipofectamine 2000 in
conjunction with Nupherin (Biomol Research Laboratories,
Plymouth Meeting, PA) according to the manufacturer’s
instructions (24). 1g of each fluorescently labeled subunit was
used.
Confocal Imaging—Neuro2a cells were plated at 90,000 cells
per dish and imaged live 48 h after transfection. Before imaging,
cell culture medium was replaced with phenol red-free CO2-
independent Leibovitz L-15 medium. Cells were imaged with a
Nikon (Nikon Instruments, Melville, NY) C1 laser-scanning
confocal microscope system equipped with a 63 1.4 numer-
ical aperture VC Plan Apo oil objective. Pinhole diameter was
30–60m, and cells were imaged at 12-bit intensity resolution
over 512  512 pixels at a pixel dwell time of 6.12 s. Cellular
mGFP and mCherry fluorescent signals were acquired by
simultaneous excitation with 488-nm (for mGFP) and 561-nm
(for mCherry) lasers. Emission spectra were acquired in 5-nm
bins between 500 and 660 nm, and the signal of each expressed
fluorophore was linearly unmixed from the raw spectral image
using reference spectra from control cells expressing only
mGFP or only mCherry fusion constructs. For each pixel of a
spectral image, intensity of mGFP and mCherry was deter-
mined from fluorescence intensity values at the peak emission
wavelength derived from the reference spectra.
Fo¨rster Resonance Energy Transfer (FRET) by Donor Recovery
after Acceptor Photobleaching (DRAP)—To examine FRET
between nAChR subunits, the acceptor photobleaching
method (21) was used with a modified DRAP macro built into
the EZC1 imaging software (Nikon). The fluorescence intensity
of mGFP and mCherry was recorded simultaneously using a
488- and 561-nm laser, respectively, during a six-step incre-
mental photodestruction of mCherry with a 561-nm laser and
normalized to the prebleach time point. ID value was extrapo-
lated from a scatterplot of the fractional increase of mGFP ver-
sus the fractional decrease of mCherry. FRET efficiency was
calculated as E  1  (IDA/ID), where IDA represents the nor-
malized fluorescence intensity of mGFP (100%) in the presence
of both donor (mGFP) and acceptor (mCherry), and ID repre-
sents the normalized fluorescence intensity of mGFP in the
presence of donor only (complete photobleaching ofmCherry).
Data were averaged from 20 to 30 cells per condition and
reported as mean	 S.E.
FRET measurements may include contributions from pairs
of fluorophores that are nearby but not in a macromolecular
complex. In the biophysical literature, this has also been termed
stochastic FRET, bystander FRET, background FRET, and
proximity FRET. King et al. (25) calculated and measured that
proximity FRET became negligible for tetramers at membrane
densities less than103 receptors/nm2 or 103 receptors/m2,
and similar estimates would apply to pentamers. The closely
packed acetylcholine receptors at the nerve-muscle synapse
have densities of 104/m2. For this study, densities on the
plasma membrane were probably 
102/m2, judging by the
7/dup7 and7/dup7 Heteropentameric nAChRs
26452 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 38•SEPTEMEBR 19, 2014
 at CA
LIFO
RN
IA
 IN
STITU
TE O
F TECH
N
O
LO
G
Y
 on O
ctober 16, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
small size of the currents we observed, by the fact that receptors
were not evident in membrane profiles, and by the fact that we
have rarely observed signals from single 7 nAChRs in mem-
brane patches studied by zero-modewaveguides (26);measure-
ments from Simonson et al. (27) yielded a similar conclusion. A
more substantial, but less measurable, source of stochastic
FRET would arise from fluorophores in the endoplasmic retic-
ulum membrane. Total internal reflection fluorescent mea-
surements of endoplasmic reticulum-resident heteromeric
nAChRs (28) have led us to the assumption that these densities
are 
103/m2; and the much lower signals observed in this
study led us to an estimate of 
102/m2 in the endoplasmic
reticulum. Thus, we conclude that proximity FRET has played
little or no role in our measurements. An abundance of caution
leads us to assume that in DRAP mode, FRET efficiencies of

10% may include a contribution from proximity FRET.
FRET by Fluorescence Lifetime ImagingMicroscopy (FLIM)—
We have monitored the fluorescence lifetime  by time-corre-
lated single-photon counting. YFP (donor)- and mCherry
(acceptor)-tagged nAChRswere co-expressed inNeuro2a cells.
We excited YFP with a picosecond pulsed laser (514 nm) and
monitored the fluorescence emission using a time-correlated
single-photon counting module (PicoQuant, West Springfield,
MA). Data were collected at 530 	 20 nm through a bandpass
filter. Laser power was adjusted to give average photon-count-
ing rates of the order 104 to 105 photons/s to avoid pulse pile up.
The decay of the YFP fluorescent intensity was fitted into either
a single exponential (when YFP is present alone) or a double
exponential (when YFP and mCherry are present) with Sym-
PhoTime software (PicoQuant) using Equation 1,
It  A1e
 t/1  A2e
 t/2 (Eq. 1)
where 1 is the fluorescence lifetime of a YFP molecule when it
is present alone, and 2 is the fluorescence lifetime of a YFP
molecule when it interacts with its acceptor mCherry. We cal-
culated the “binding fraction” and FRET efficiency using Equa-
tions 2 and 3,
PFRET 
A2
A1 A2
(Eq. 2)
EFRET  1
2
1
(Eq. 3)
where PFRET is the binding fraction, the fraction of YFP mole-
cules that interact with mCherry, and EFRET is the FRET
efficiency.
Whole-cell Patch Clamp Recordings—Neuro2a cells were
plated on 12-mm glass coverslips within 35-mm plastic bottom
cell culture dishes at the density of 50,000 cells per dish. 48–72
h after transfection, glass coverslips were transferred to the
recording chamber on the microscope stage. Expressing cells
were identified and visualized as follows. Green (mGFP) and
red (mCherry) fluorescence was visualized with an upright
microscope (BX50WI, Olympus) and UV illumination with
appropriate excitation filters. Cells were voltage-clamped at a
holding potential of 65 mV. Agonists were applied using a
focal drug application system to minimize desensitization (29).
For concentration-response studies, ACh was applied from the
lowest to highest concentration at 3-min intervals to get the
dose-response curve. Whole-cell patch clamp recordings were
performed with a MultiClamp 700B amplifier, a 1322 analog-
to-digital converter, and pCLAMP 9.2 software (all from Axon
Instruments, Molecular Devices). Data were sampled at 10 kHz
and filtered at 2 kHz.
The intrapipette solution contained (in mM) the following:
135 potassium gluconate, 5 KCl, 5 EGTA, 0.5 CaCl2, 10 HEPES,
2 Mg-ATP, and 0.1 GTP; the pH was adjusted to 7.2 with Tris
base and the osmolarity to 300 mOsM with sucrose. The extra-
cellular solution contained (in mM) the following: 140 NaCl, 5
KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 glucose; pH was
adjusted to 7.3 with Tris base. The Nernst potential for Cl in
the intrapipette solution is 82.9 mV. The bath was continu-
ously perfusedwith extracellular solution at room temperature.
The patch electrodes had resistances of 5–8 megohms. The
junction potential between the patch pipette and the bath solu-
tions was nulled just before forming a seal. Series resistancewas
monitored and compensated by 70–80% throughout the
recordings. The data were ignored if the series resistance
(15–30 megohms) changed by 20% during the recording
session.
For the substituted cysteine accessibility method (SCAM),
each cell received one initial baseline application of ACh (300
M), one control ACh application, an application of ethylam-
monium methanethiosulfonate (MTSEA, 2 mM, Toronto
Research Chemicals Inc., North York, ON, Canada), and then a
follow-up experimental application of ACh. The peak ampli-
tude of control responses and experimental responses were cal-
culated relative to baseline ACh responses to normalize the
data.
RESULTS
Co-localization of Fluorescently Labeled dup7/dup7
Subunits and the Full-length 7—Based on previous work (21,
22), we fused fluorescent protein to the M3-M4 loop of full-
length human 7 nAChRs as well as the dup7 and dup7
subunits (Fig. 1A). Fluorescently labeled subunits are co-ex-
pressed in Neuro2a cells and imaged alive using a confocal
microscope (Fig. 1B). We noted that the heterologous expres-
sion of duplicated subunits was low. The chimeric gene,
CHRFAM7A, is transcribed efficiently, but translation is poor
(19). The intensity of the FP attached to these subunits was
5% of the intensity of the FP attached to the full-length sub-
units. When co-expressed with fluorescent 7, the duplicated
subunits were localized primarily in the endoplasmic reticu-
lum, similar to the localization of the full-length receptors. We
did not systematically study localization at the plasma mem-
brane. The merged images of the GFP and mCherry signals
indicate that both dup7 and dup7 subunits co-localize with
the full-length 7 receptor very well. Pearson correlation coef-
ficients were as follows: 7GFP with dup7mCherry, 0.96 (n
26); 7GFP with dup7mCherry, 0.95 (n  25); dup7GFP
with 7mCherry, 0.96 (n  27); and dup7GFP with
7mCherry, 0.97 (n  26). We then co-expressed the dupli-
cated and the full-length subunits in primary rat hippocampal
neurons. Because of the low intensity of the labeled duplicated
7/dup7 and7/dup7 Heteropentameric nAChRs
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subunits, theywere not detected in the distal sites such as axons
anddendrites. In the cell soma,wherewewere able to detect the
duplicated subunits, both dup7 and dup7 were co-local-
ized with the full-length 7 (Fig. 1C). Pearson correlation coef-
ficients were as follows: 7GFP with dup7mCherry, 0.85 (n
11); 7GFP with dup7mCherry, 0.86 (n  11); dup7GFP
with 7mCherry, 0.93 (n  10); and dup7GFP with
7mCherry, 0.91 (n 12).
Interaction between dup7/dup7 Subunits and the Full-
length 7, DRAP Assays—The fact that the duplicated and the
full-length subunits are co-localized both in Neuro2a cells and
in the cell body of neurons suggests that theymay be assembled
into oligomers. The receptor assembly of nicotinic subunits is
often measured by immunoprecipitation (30). This approach
has limited applicability, however, for dup7 and dup7, due
both to the extremely low protein levels and the lack of immune
reagents selective for the duplicated subunits.
To directly determinewhether the duplicated subunits inter-
act with the full-length 7, we measured FRET between fluo-
rescently tagged receptor subunits. FRET occurs only when
donors and acceptors are within100Å.When the fluorescent
proteins are fused into the M3-M4 loop of nicotinic receptor
subunits, subunits within pentamers undergo FRET. We have
previously developed experimental approaches, well supported
by theory, to analyze the assembly and subunit stoichiometry of
such subunits withinCys loop receptors (23, 28, 31–33). For the
present experiments, important guidelines arise from the
strong distance dependence of FRET. Thus, for DRAP experi-
ments adjacent subunits have considerably higher FRET values
than nonadjacent subunits, and a donor adjacent to two accep-
tors displays higher FRET than one adjacent to zero or one
acceptor.
We first employed DRAP to measure FRET between sub-
units (34). An mGFP/mCherry FRET pair was used for good
separation of the excitation and emission spectra. We incre-
mentally bleached mCherry at 561 nm while monitoring fluo-
rescence intensity of both mGFP and mCherry, at 488 and 561
nm, respectively. Changes in fluorescence intensity versus time
were plotted for each cell, and FRETefficiencywas calculated as
described under “Experimental Procedures.” DRAP data
revealed several types of co-assembly as follows: 7 with 7; 7
with dup7; 7 with dup7; dup7 with dup7; and dup7
with dup7 (Fig. 2A). The measured FRET efficiencies were
different between reciprocal pairs. FRET efficiency was greater
when dup7, or dup7, was the donor. This is likely due to the
low expression of the duplicated gene; a dup7 subunit is more
likely to lie adjacent to an 7 subunit in the heteromeric
receptor.
To confirm the interaction between the duplicated subunits
and the full-length subunit, we measured FRET between
7-mGFP and 7-mCherry when untagged competing sub-
units were co-expressed. Calculated FRET efficiency showed
that co-expression of untagged subunits, either duplicated or
full-length, significantly decreased the FRET efficiency of the
7-mGFP/7-mCherry pair (Fig. 2B), suggesting the specific
interaction between dup7/dup7 subunits and the full-
length 7.
FIGURE 1. Co-localization of fluorescently labeledduplicated subunitswith
full-length 7 in representative confocal cross-sections. A, schematics of
fluorescently labeled constructs. 7 is full-length human 7 nAChR; dup7 is
partial duplicationof human7;dup7 is partial duplicationof human7with
a 2-bp deletion. Black boxes represent transmembrane domains; gray box repre-
sents duplication of sequences from gene ULK4 on chromosome 3, and striped
boxes represent fluorescent proteins fused into the M3-M4 loop of nAChRs. B,
duplicated subunits and full-length 7 receptors are localized similarly in
Neuro2a cells. Neuro2a cells were transfected with the indicated nAChR cDNAs
andwere imaged live with spectral confocal microscopy 48 h after transfection.
Spectral images were acquired, and specific mGFP and mCherry signals were
extracted with linear unmixing. Fluorophore abbreviations are as follows: G,
mGFP; Ch, mCherry. Green (mGFP signal) and red (mCherry signal) pseudocolor
was assigned, and yellow (Merge) indicates co-localized proteins. C, duplicated
subunits and full-length 7 receptors are localized similarly in the cell soma in
primary neurons. E18 rat hippocampal neurons were plated and cultured for 14
days followed by transfection with the indicated nAChR cDNAs. One day after
transfection, cells were imaged live using confocal microscopy. Normalization
was done to emphasize co-localization and differed for the full-length versus
duplicated constructs.Without normalization, themerged signal ismostly green
(when7mGFP isexpressed)or red (when7mCherry isexpressed)andprovides
little information about co-localization. All images in C are less bright than B
because the overall protein expression level is lower in primary neurons (C) than
inNeuro2a cells (B). Scale bar, 10m.
7/dup7 and7/dup7 Heteropentameric nAChRs
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Potential Stoichiometry of 7dup7 and 7dup7 Hetero-
mers, FLIM Measurements—DRAP is not optimal for deter-
mining subunit stoichiometry in the present experiments
because there are many more full-length 7 subunits than
duplicated subunits when they are co-expressed (32). We also
employed FLIM tomeasure FRET. The fluorescence decay pro-
file of the donor, YFP molecules, was acquired from the entire
cell with the use of a time- and space-correlated single-photon
counting detector and was fitted to a double exponential
time course (Fig. 3A). Neuro2a cells transfected with various
nAChR cDNAsweremonitored alive. The binding fraction, the
fraction of donor that interacts with the acceptor, and FRET
efficiency were calculated as described under “Experimental
Procedures.” In the context of analyses presented elsewhere, we
believe that the binding fraction is best interpreted as the frac-
tion of donors adjacent to one ormore acceptors (23, 28, 31, 32).
These twometrics are relatively insensitive to fluorophore con-
centration and light-path length, conditions that are poorly
controlled inside a cell (35, 36). FLIM data confirmed several
types of co-assembly as follows: 7 with 7; 7 with dup7; 7
with dup7; dup7 with dup7; and dup7 with dup7
(Fig. 3B).
To investigate the stoichiometry of 7/dup7 and 7/dup7
heteromers, we measured FRET between various pairs when
untagged competing subunits were co-expressed. Both binding
fraction and FRET efficiency of the 7-YFP/7-mCherry pair
were decreased, as expected, by untagged full-length 7 (Fig. 3,
C1 andC2). Interestingly, co-expression of untagged duplicated
7 decreased binding fraction but not FRET efficiency of the
7-YFP/7-mCherry pair, suggesting a limited incorporation
of the duplicated subunits. In an (7-YFP)1(7-mCherry)4 con-
figuration, as the number of untagged full-length subunits
increases, the donor is less likely to be adjacent to an acceptor,
which results in a decrease in the binding fraction. In contrast,
if only one acceptor can be replaced by the duplicated subunit,
the donor is still adjacent to an acceptor; thus one expects only
a modest change in the binding fraction, and this is observed
experimentally (Fig. 3C1). Furthermore, when untagged full-
length 7 was co-expressed for competition, both binding frac-
tion and FRET efficiency of dup7-YFP/7-mCherry and
dup7-YFP/7-mCherry pairs were decreased significantly.
The difference between the reciprocal conditions, dup7 com-
peting for 7-YFP/7-mCherry pair and 7 competing for
dup7-YFP/7-mCherry pair, also supports the limited incor-
poration of duplicated subunits; more than one acceptor can be
replaced by untagged subunits when 7 is competing, decreas-
ing FRET substantially.
FRET Shows Assembly of dup7 and dup7 Subunits with
Other Nicotinic Acetylcholine Subunits—We examined whether
the duplicated subunits interactwith other nicotinic receptor sub-
units. We co-expressed 4-mCherry or 3-mCherry subunits
with YFP-tagged 7 subunits, either duplicated or full-length,
in Neuro2a cells and measured FRET using FLIM (Fig. 4).
Extensive quantitative analysis is not possible because of two
complicating factors (32). 1) The 4, 3, and 7 subunits differ
substantially in the size of theirM3-M4 regions. 2) The fluores-
cent proteins may be inserted at differing orientations within
these nonhomologous loops. Nonetheless, the results showed
that both duplicated and full-length 7 interacted with 4 sub-
units (Fig. 4, A1 and A2). The FRET efficiency of a reciprocal
pair, 4-YFP/7-mCherry, was comparable with that of the
7-YFP/4-mCherry pair, but the binding fraction is lower,
probably due to larger numbers of 4-YFP subunits in the cells.
The FRET efficiency of dup7-YFP/4-mCherry was higher
than that of the 7-YFP/4-mCherry pair, suggesting that 7
subunits, both duplicated and full-length, assembledwith4 into
trimersorhigherordermultimers. If7-YFPanddup7-YFPonly
form dimers with 4-mCherry, the FRET efficiency will be the
same for 7-YFP/4-mCherry and dup7-YFP/4-mCherry.
To confirm the specificity of the interaction detected by
FLIM, we co-expressed untagged competing 4 subunits with
the 7-YFP/7-mCherry pair; both binding fraction and FRET
efficiency were decreased (Fig. 4,C1 andC2). In contrast, co-ex-
pression of untagged GABA transporter GAT1 (31) had no
effect on the7-YFP/7-mCherry pair.When untagged7was
used for competition, binding fraction but not FRET efficiency
of the 7-YFP/4-mCherry pair was decreased, whereas both
binding fraction and FRET efficiency of dup7-YFP/4-
mCherry and dup7-YFP/4-mCherry pairs were affected
(Fig. 4, D1 and D2). Furthermore, both full-length and dupli-
FIGURE 2.DRAP revealed assembly of duplicated subunitswith full-length7. A, FRET efficiencywasmeasured byDRAP in Neuro2a cells. Several types of
co-assembly were detected as follows: 7 with 7; 7 with dup7; 7 with dup7; dup7 with dup7; and dup7 with dup7. B, co-expression of
untagged competing subunits decreased the FRET efficiency of the 7-mGFP/7-mCherry pair. Error bars are	 S.E., and n 20–30 cells for each condition.
**, p
 0.01 compared with first condition.
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cated 7 display robust FRET with 3 nAChR subunits (Fig. 4,
E1 and E2).
dup7 and dup7 Subunits Form Functional Receptors
with 7 Subunits—The SCAM is appropriate to identify the
residues lining the lumen of ion channels (37, 38). The cysteine
sulfhydryl forms a disulfide bond with sulfhydryl-specific
reagents, methanethiosulfonate (MTS) derivatives, including
MTS-ethylammonium (MTSEA), ethyltrimethylammonium,
and ethylsulfonate. A cysteine mutation is generated to replace
a particular residue; if this residue lies in the lumen of the ion
channel and is accessible from the extracellular solution, MTS
derivatives alkylate the cysteine and alter ion channel function.
Leucine at the 247-position of 7 nicotinic receptors resides
9 residues downstream from the cytoplasmic beginning of the
M2 pore-lining region (termed the 9-position in most studies,
because the M2 domain is rather well conserved among Cys
loop receptors). TheM2 domain of dup7 and dup7 has the
same sequence as 7 in this domain. We replaced the Leu-9
residue with cysteine (L9C mutation) in dup7 and dup7.
We transfected these subunits individually with 7 subunits
and measured receptor function with the whole-cell patch
clamp technique. If dup7 and dup7 subunits assemble with
7 subunits to form functional receptors, we expect the intro-
duced cysteines in dup7 and dup7 to be accessible for
MTSEA and MTSEA to change receptor function. As the 7
subunit has a cysteine at the 116-position, to eliminate the pos-
sibility that MTS derivatives bind to the endogenous cysteine
and distort the results, we replaced this cysteine with serine in
all of the constructs. The aligning mutation in dup7 and
dup7 has different numbers but are termed C116S for con-
sistency. Previous reports show that the C116S does not alter
7 receptor function (39).
Using the whole-cell patch clamp technique and a focal drug
application system (29, 40), we examined 300 M ACh-evoked
inward current (IACh) at 3-min intervals (Fig. 5A1). In cells sat-
isfying the criterion of stable baseline responses (
15% varia-
tion in 10min), we subsequently perfused the cell with standard
extracellular solution for 3 min to wash out ACh, applied 2 mM
MTSEA for 2 min, washed out MTSEA for 5 min, and puffed
300MACh to evoke IACh (Fig. 5A2).We compared IACh before
and after MTSEA application to test whether MTSEA changed
receptor function. Changes in agonist-induced currents indi-
FIGURE 3. FLIM confirmed assembly of duplicated subunits with full-length 7. A, schematic of FRET occurring when a donor, the YFP (yellow-green
cylinder) molecule attached to a nAChR subunit (gray cylinder), and an acceptor, themCherry (red cylinder) molecule attached to a nAChR subunit, are in close
proximity, usually
10 nm. The nonradiative transfer of excited state energy of the donor to the acceptor shortens the donor fluorescence lifetime and results
in a faster decay in the fluorescence intensity of thedonors.B1 andB2, Neuro2a cellswere transfectedwith the indicatednAChR subunits andwere imagedalive
using FLIM. Binding fraction (B1) and FRET efficiency (B2) were calculated as described under “Experimental Procedures.” Several types of co-assembly were
detected as follows:7with7,7with dup7,7with dup7, dup7with dup7, and dup7with dup7.C1 andC2, additional expression of untagged
competing subunits (black circles) decreased the binding fraction of the 7-YFP/7-mCherry pair. **, p 
 0.01; *, p 
 0.05 versus first condition. D1 and D2,
additional expression of untagged full-length 7 subunit decreased both binding fraction and FRET efficiency of the dup7-YFP/7-mCherry and dup7-
YFP/7-mCherry pairs. Error bars are	 S.E., and n 20–30 cells for each condition. **, p
 0.01; *, p
 0.05.
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cate that the receptors include subunits with the cysteine
mutation.
We transfected Neuro2a cells with 7 DNA constructs con-
taining the C116S mutation. As a control, we transfected
7-mCherry, 7-mCherry  dup7-GFP, or 7-mCherry 
dup7-GFP into Neuro2a cells and tested whether MTSEA
changed receptor function. As expected, MTSEA did not
change IACh in the transfected cells (Fig. 5, B1, C1, and D1),
confirming that introducing the C116Smutation was sufficient
to prevent MTSEA from affecting the receptor’s function. We
next transfected7-mCherry with both C116S and L9Cmuta-
tions into Neuro2a cells. In this situation, all of the subunits in
the functional receptors are accessible to MTSEA. Indeed, we
observed that MTSEA inhibited IACh by 54 	 7% (n  5, p 
0.002) (Fig. 5, B2 and E1). These results indicated that the assay
was valid to reveal whether cysteine-containing subunits exist
in functional receptors.
We next tested whether MTSEA changes receptor function
in Neuro2a cells transfected with 7-mCherry containing the
C116S mutation and either the dup7-GFP or dup7-GFP
construct containing both C116S and L9‘C mutations. We
recorded IACh from cells showing both GFP and mCherry fluo-
rescence and found thatMTSEA, respectively, inhibited IACh by
63	 5% (n 7, p
 0.0001) and by 43	 2% (n 6, p
 0.0001)
in cells expressing dup7-GFP  7-mCherry and dup7-
GFP  7-mCherry (Fig. 5, C2, D2, and E2). Note that the
MTSEA effects on these cells were similar to those on cells
expressing 7-L9C subunits only. These results suggested that
both dup7 and dup7 subunits were able to form functional
receptors with 7 subunits, and in this expression system,most
functional receptors had dup7 or dup7 subunits.
SCAM analysis suggests that in Neuro2a cells dup7 or
dup7 subunits commonly assemble with 7 subunits form-
ing functional receptors. To understand whether the presence
of dup7 or dup7 subunits changes function of7 receptors,
we tested the dose-response relationship of IACh in Neuro2a
cells transfected with 7 only, 7  dup7, or 7  dup7
subunits (Fig. 6,A–C). IACh in all transfected cells reachedmax-
imum levels when ACh exceeded 1 mM (Fig. 6D). The shifts of
dose-response curves were not statistically significant (Fig. 6D).
The Hill efficient was similar in 7 only (1.51 	 0.25), 7 
dup7 (1.48 	 0.34), or dup7  7 (1.60 	 0.44), and the
EC50 value was similar in 7 only (192 	 21 M), 7  dup7
(158	 24 M,) and 7 dup7 cells (218	 31 M), respec-
tively. These data suggest that the presence of dup7 and
dup7 does not alter the ACh sensitivity of 7 receptors.
FIGURE 4. FLIM revealed potential interaction of duplicated subunits with other nAChR subtypes. A1 and A2, Neuro2a cells were transfected with
indicated nAChR subunits and were imaged alive using FLIM. Binding fraction (A1) and FRET efficiency (A2) were calculated. 7, dup7, and dup7 interact
with the human 4 subunit. B, schematic of FRET between donors and acceptors in a dimer or trimer. The yellow circle represents the donor (YFP molecule
attached to a nAChR subunit), and the red circle represents the acceptor (YFP molecule attached to a nAChR subunit). An arrow represents energy transfer
between thedonor and theacceptor.C1 andC2, co-expressionofuntagged4, butnotGAT1, decreased theFRETbetween the7-YFP/7-mCherrypair.D1 and
D2, co-expression of untagged full-length 7 subunit decreased the FRET between the 7-YFP/4-mCherry, dup7-YFP/4-mCherry, and dup7-YFP/4-
mCherry pairs. E1 and E2,7, dup7, and dup7 interact with the human3 subunit. Error bars are	 S.E., and n 20–30 cells for each condition. **, p
 0.01;
*, p
 0.05.
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Channel Properties of dup7/7 and dup7/7 Hetero-
mers—We next tested whether dup7 and dup7 subunits
affect the responses of 7 receptors to choline, another endog-
enous agonist, and to varenicline, a full agonist.We activated7
receptors by puffing (20 p.s.i.) 100 M choline or 10 M vareni-
cline (both are less than EC50) (41, 42) (Fig. 7, A1 and B1, upper
panels). On the same cell, we applied 1 mM ACh to evoke max-
imal activation of 7 receptors (Fig. 7,A1 and B1, lower panels).
Thenwenormalized choline- and varenicline-induced currents
to 1 mM ACh-evoked currents (Fig. 7, A2 and B2). This process
reduced the variability introduced by differences in plasma
membrane receptor numbers among individual cells, and by
the process of deliberately selecting fluorescent cells. Choline
induced a larger relative current in cells expressing dup77
subunits (14	 2%, n 8) than those expressing either 7 sub-
units alone (8	 1%, n 6) or dup7 7 subunits (6	 1%,
n  7) (p  0.01, one-way analysis of variance) (Fig. 7A2).
Varenicline-induced currents were significantly larger in cells
expressing dup7  7 subunits (45 	 5%, n  7) than in
those expressing 7 subunits alone (24 	 4%, n  8) or those
expressing dup7  7 subunits (33 	 5%, n  10) (p  0.02,
FIGURE 5. SCAM evidence for the co-assembly of 7 and dup7 or
dup7 subunits in functional nAChRs.A1, picture showing thewhole-cell
patch clamp recording from a Neuro2a cell, and the application of ACh and
MTSEA.A2, timeline of ACh andMTSEA application.MTSEAdid not change7
receptor function in cells expressing 7 subunit alone (B1), 7 dup7 sub-
units (C1), and 7  dup7 subunits (D1). When the L9C mutation was
introduced into 7 subunits, MTSEA inhibited ACh-induced currents (B2).
When the L9C mutation was introduced into dup7 and dup7, MTSEA
attenuated ACh-induced currents in cells expressing 7  dup7 subunits
(C2) and 7 dup7 subunits (D2). E1 and E2, summary of MTSEA effects on
each group of cells. All subunits also included the C116S or aligning muta-
tions. Numbers in parentheses indicate the number of cells examined.
FIGURE 6. dup7 and dup7 subunits did not changeACh responses of
7 receptors. Responses to 30–3000 M ACh were recorded from cells
expressing 7 subunits (A), 7  dup7 subunits (B), and 7  dup7
subunits (C). The peaks of ACh currents were normalized to those of the 1mM
ACh-induced ones in individual cells, and the normalized currents were used
to depict dose-response curves (D). Each point is averaged from 5–9 cells and
is shown as mean 	 S.E. The 1 mM ACh-induced currents are shown in box
plots (E). Numbers in the box indicate the numbers of cells.
FIGURE 7. Choline- and varenicline-evoked 7 currents. Choline (100 M)
(A1) and varenicline (10 M) (B1) induced inward currents in Neuro2a cells
expressing7 subunits,7dup7 subunits, and7dup7 subunits. In
the same cells, 1 mM ACh-induced currents were also recorded (lower panels
in A1 and B1). The responses of choline and varenicline were normalized to
those of 1 mM ACh, and the normalized responses were illustrated in A2 and
B2, respectively. Numbers in parentheses indicate the number of cells exam-
ined. *, p
 0.05.
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one-way analysis of variance) (Fig. 7B2). These data suggest that
the presence of dup7 subunits may increase the sensitivity of
7 receptors to choline, but co-assembly of dup7 with 7
subunits produced no significant change in sensitivity com-
pared with homopentameric 7 receptors. However, the pres-
ence of dup7 subunits may enhance the sensitivity of 7
receptors to varenicline.
Because 1mMACh evoked near-saturating currents, activat-
ing the great majority of 7 receptors (Fig. 6D), the size of 1mM
ACh-induced currents may correlate well with the number of
functional receptors. We compared 1 mM ACh-induced cur-
rents in cells expressing 7 subunits alone, 7  dup7 sub-
units, and 7  dup7 subunits 72 h after transfection. As
illustrated in Fig. 6E, the peak amplitude of IACh did not differ
among groups of cells. These data suggest that dup7 and
dup7 did not alter the number of7 receptors.We acknowl-
edge that ascertainment bias could have been introduced by the
process of identifying and studying the fluorescent cells.
We applied 100 M ACh and 100 M choline for relatively
prolonged pulses lasting 2 s, whereas we measured voltage-
clamp currents (Fig. 8, A1 and B1). Such experiments represent
the classical tests for desensitization kinetics of nAChRs. As
shown in Fig. 8,A2 andB2, we found that the presence of dup7
and dup7 did not alter the desensitization kinetics of 7
receptors in the presence of ACh and choline. In all cases,
desensitization was nearly complete during the pulse.
Endogenous choline levels are around 35 M in the neonatal
nervous system, and become3 times lower in the adult (43). It
remains unknownwhether the loss of function in a schizophre-
nia patient carrying dup7 receptors comes from less activa-
tion by choline, accelerated desensitization, or more complete
desensitization of 7 receptors in the presence of choline at
circulating concentrations. To address these issues, we tested
receptor activation by 20M choline, and we compared 200M
ACh-induced currents before and after preincubation with 20
Mcholine for 1–60 s (Fig. 8,C1 andC2). 20Mcholine induced
FIGURE 8.Desensitization of 7 receptors. 100 M ACh (A1) or 100 M choline (B1) was applied for 2 s to Neuro2a cells expressing 7 subunits, 7 dup7
subunits, and7dup7 subunits. The decay time constants of these responsesweremeasured and summarized inA2 and B2.C1, prolongedpreincubation
with 20Mcholine reversibly attenuated7 receptor currents inducedby 200MACh.C2, time course of desensitizationby 20Mcholine. Eachpoint in C2was
averaged from 5 to 9 cells expressing 7 subunits only (red circle), 7 dup7 subunits (blue triangle), or 7 dup7 subunits (brown circle).
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no detectable currents in all cells we recorded (data not shown).
Preincubation with 20 M choline up to 5 s reversibly attenu-
ated ACh currents by 50% in cells expressing 7 subunits
alone, dup77 subunits, and dup77 subunits (Fig. 8,
C1 and C2). The briefest preincubations with choline, 1 or 2 s,
reversibly attenuated ACh-induced currents in cells expressing
7 subunits alone by 14 	 3% (n  6) and 24 	 3% (n  5),
respectively. Interestingly, the attenuations were significantly
greater in cells expressing 7 dup7 subunits (1-s choline by
34 	 8%, n  7; 2-s choline by 44 	 11%, n  5) and 7 
dup7 subunits (1-s choline by 30	 7%, n 5; 2-s choline by
44	 5%, n 5) (Fig. 8C2). These results support the hypothesis
that the presence of dup7 and dup7 enhances some aspects
of choline-induced desensitization at 7 receptors.
DISCUSSION
Exons 1–6 of CHRNA7 correspond to the receptor’s extra-
cellular N-terminal region, which contains the ligand-binding
domain. Exons 7 and 8 correspond to the first three transmem-
brane regions, M1, M2 and M3, and M2 constitutes the ion
channel of the receptor (44). Exons 9 and 10 encode its intra-
cellular cytoplasmic loop, the fourth transmembrane region,
M4, and the extracellular C terminus. CHRFAM7A, containing
only exons 5–10 of CHRNA7, lacks the signal peptide as well as
part of the extracellular N-terminal region, including one of
the three N-glycosylation sites. This lack of a ligand-binding
domain renders it unsurprising that dup7, when expressed
alone in Xenopus oocytes or Neuro2a cells, fails to produce
ACh-induced current. In addition, previous studies have dem-
onstrated that the N-terminal extracellular domain of nAChR
plays a leading role in mediating assembly and determines the
specificity of the intersubunit recognition (45–47). This study
confirms that in a heterologous expression system, a truncated
nAChR subunit lacking both signal peptide and part of the
N-terminal extracellular domain is 1) processed in a similarway
as the full-length subunit; 2) assembledwith the full-length sub-
unit; 3) trafficked to the cell membrane; and 4) incorporated
into a functional channel.
Although the N-terminal extracellular domain is important
for the initial association between subunits, a downstream
domain, the cytoplasmic loop betweenM1 andM2, participates
in the subsequent interaction and stabilization of the oligo-
meric complex (48). Further downstream, theM3-M4 intracel-
lular loop also affects nAChR assembly (49, 50). Assembly of
dup7 and dup7 with full-length 7 suggests that other
regions of sequence may mediate the interaction between sub-
units and thus compensate for the lack of the N terminus.
The duplicated subunits also interact with other nAChR sub-
types, such as 4 and 3, suggesting that they may have broad
effects on nAChR function, depending on the cell types and
brain regions in which they are expressed. Because the N-ter-
minal extracellular domain controls specificity of subunit inter-
action, future studies should examine whether duplicated sub-
units assemble with other Cys loop receptors, such as serotonin
5-HT3, that do not normally interact with full-length7.We do
not know whether the interactions of the duplicated 7 sub-
unit, found here in the admittedly forced heterologous system,
also occur in human neurons.
Immunostaining of dup7 overexpressed in SH-EP cells con-
firmed that translated peptide contains the sequence for the 7
subunit (19). The translation of CHRFAM7A2bp, however, is
based only on prediction. When the 2-bp deletion in exon 6 is
present, translation is likely to start at one of the two initiating
methionines in exon 6. The peptide is out of frame for either 6
or 13 amino acids, depending on which ATG is used, until the
2-bp deletion is reached. At that point, the amino acid sequence
returns to the reading frame of the 7 subunit. The resulting
protein, dup7, is smaller than dup7 and lacks a larger por-
tion of the agonist-binding domain.We fused a fluorescent pro-
tein into theM3-M4 loop of dup7 and expressed the labeled
protein in Neuro2a cells. Fluorescent signals were observed,
and they overlap with the signals from fluorescently labeled
full-length 7. Our confocal imaging data confirmed that
dup7 is indeed translated, and the protein is in-frame
with 7.
We have studied the effect of the duplicated 7 genes on 7
nAChR function. In theory, they could regulate receptor
expression and function in other ways, such as at the RNA level.
Furthermore, several ATGs in CHRFAM7A could result in
truncated transcripts that do not contain CHRNA7 coding
sequence. Because of the frameshift in CHRFAM7A2bp, use
of the dup7 subunit initiating methionine would encode a
unique 40-amino acid peptide, terminated by a stop codon.
With no homology to 7, it is unlikely that such a truncated
peptide would assemble with 7 subunits.
The duplicated subunits may have a role in inflammatory
responses. Recent studies described 7 nAChR as a link in the
cholinergic anti-inflammatory pathway and an anti-inflamma-
tory target (51–53). dup7 is highly expressed in macrophages,
and it is down-regulated at themRNA level by IL-1, LPS, and nic-
otine (20, 54). Duplicated subunits could therefore modulate 7
receptor-mediated cholinergic anti-inflammatory responses. We
noted that co-expression of 7 increased the proportion of
dup7-expressing cells by 2-fold (data not shown); we do not
know whether this occurred because 7 enhances dup7
mRNA expression or acts as a protein chaperone for dup7
survival. Thus, investigating dup7/7 pathways may have
medical applications in the treatment of inflammatory
disorders.
We found that co-expression of either duplicated subunit
with 7 subunits in mammalian cells had no marked effects on
ACh-induced currents. This finding contrasts with previous
studies in oocytes, showing a dominant negative effect of dup7
on the full-length receptor (19, 20). Many previous studies
show that ion channels and receptors assemble differently in
these two expression systems, probably in several ways. First,
dup7 and dup7 genes and proteins are expressed at
extremely low levels in mammalian cells. Although we used
equimolar amounts of 7 and dup7 DNA for transfection, the
actual mRNA and protein ratio of dup7/7 was probably 1:10
or lower. Because small amounts of dup7 subunits were pres-
ent, few 7/dup7 heteromers included more than one dup7
subunit. A previous study shows that nAChRs containing only a
single non-7 subunit, and therefore lacking two 7-7 inter-
faces, do function rather well (55); but an additional non-7
subunit does abolish function (55). This surfeit of dup7 or
7/dup7 and7/dup7 Heteropentameric nAChRs
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dup7 subunits may be possible in oocytes, producing the
apparent dominant negative effect, but apparently not in the
present mammalian system. Second, our studies in Neuro2a
cells also included RIC-3 (resistant to inhibitor of cholinester-
ase) expression. RIC-3 is an endoplasmic reticulum chaperone
for nAChRs (56–58). The effects of theRIC-3 level on7 recep-
tors display an inverted U-shape dose-response relation (57).
RIC-3 also shows differential effects when co-expressed with
various ligand-gated ion channels as follows: enhancing func-
tional expression of multiple nAChR subtypes and inhibiting
5-HT3 receptors and several nAChR subtypes, including 34,
but had no effect on either GABA or glutamate receptors (59–
61). We co-expressed RIC-3 in Neuro2a cells for all our elec-
trophysiological experiments to enable functional expression of
7 on the cellmembrane. However, we do not knowwhat influ-
ence RIC-3 may have on duplicated subunits and how RIC-3
may regulate the effect of duplicated subunits on full-length 7
receptors.
Although we did not observe a significant difference in the
ACh response of 7 receptors when dup7 or dup7 was
co-expressed, dup7/7 did display a lower choline sensitiv-
ity than dup7/7 heteromers. In addition, dup7/7 or
dup7/7 receptors desensitize more quickly during brief (1
to 2 s) exposure to physiological concentrations of choline.
Genetic and neurobiological studies suggest that choline avail-
ability may contribute to the development of schizophrenia-
associated sensory gating deficits (62), and perinatal dietary
choline supplementation has been tested for lowering schizo-
phrenia risk, with positive results (63). The copy of the dupli-
cated gene with the 2-bp deletion, CHRFAM7A2bp, is found
muchmore frequently in schizophrenic patients than in control
subjects with no mental illness (16) and is associated with
abnormal sensory processing (64). Our electrophysiological
data, suggesting that dup7 lacks the augmentation of choline
sensitivity produced by dup7, may be relevant to a decreased
efficacy of choline during development in subjects that carry
this 2-bp deletion.
Varenicline produces improved cognitive performance in
schizophrenic patients (65–67). The underlying mechanisms
remain unclear because varenicline activates at least three types
of nAChRs. It is a partial agonist for 42 (EC50 2.3M, with
maximal efficacy of 13% relative to ACh) and 34 (EC50 55
M with maximal efficacy of 75% relative to ACh) nAChRs but
a full agonist for 7 nAChRs (EC50 18M) (42).We observed
a moderately enhanced sensitivity of 7/dup7 nAChRs rel-
ative to 7 and 7/dup7 receptors, supporting the present
concepts that 7 nAChRs are promising targets for develop-
ment of drugs to treat cognitive impairment in schizophrenia.
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